Artículos de revistas sobre el tema "Heterologous prime-boost"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Heterologous prime-boost".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Lu, Shan. "Heterologous prime–boost vaccination". Current Opinion in Immunology 21, n.º 3 (junio de 2009): 346–51. http://dx.doi.org/10.1016/j.coi.2009.05.016.
Texto completoPan, Chien-Hsiung, Hui-mei Hu, Yu-Ju Hsiao y Sze-Hsien Wu. "Heterologous prime-boost vaccination with DNA vaccine and recombinant subunit containing four serotypes of dengue virus envelope protein domain III elicits neutralizing antibodies and specific T-cell responses (P4327)". Journal of Immunology 190, n.º 1_Supplement (1 de mayo de 2013): 123.27. http://dx.doi.org/10.4049/jimmunol.190.supp.123.27.
Texto completoTang, Xian y Zhiwei Chen. "Heterologous immunization induces potent anti-SIV immunity with qualitative and quantitative improvements (53.22)". Journal of Immunology 186, n.º 1_Supplement (1 de abril de 2011): 53.22. http://dx.doi.org/10.4049/jimmunol.186.supp.53.22.
Texto completoZHANG, G., V. T. T. HUONG, B. BATTUR, J. ZHOU, H. ZHANG, M. LIAO, O. KAWASE et al. "A heterologous prime-boost vaccination regime using DNA and a vaccinia virus, both expressing GRA4, induced protective immunity againstToxoplasma gondiiinfection in mice". Parasitology 134, n.º 10 (17 de mayo de 2007): 1339–46. http://dx.doi.org/10.1017/s0031182007002892.
Texto completoGarg, Ishan, Abu Baker Sheikh, Suman Pal y Rahul Shekhar. "Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review". Infectious Disease Reports 14, n.º 4 (20 de julio de 2022): 537–46. http://dx.doi.org/10.3390/idr14040057.
Texto completoFolegatti, Pedro M., Amy Flaxman, Daniel Jenkin, Rebecca Makinson, Lucy Kingham-Page, Duncan Bellamy, Fernando Ramos Lopez et al. "Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies". Vaccines 9, n.º 3 (16 de marzo de 2021): 262. http://dx.doi.org/10.3390/vaccines9030262.
Texto completoCarlétti, Dyego, Denise Morais da Fonseca, Ana Flávia Gembre, Ana Paula Masson, Lívia Weijenborg Campos, Luciana C. C. Leite, Andréa Rodrigues Pires et al. "A Single Dose of a DNA Vaccine Encoding Apa Coencapsulated with 6,6′-Trehalose Dimycolate in Microspheres Confers Long-Term Protection against Tuberculosis in Mycobacterium bovis BCG-Primed Mice". Clinical and Vaccine Immunology 20, n.º 8 (5 de junio de 2013): 1162–69. http://dx.doi.org/10.1128/cvi.00148-13.
Texto completoDai, Ming-Shen, Ren-In You, Yu-Feng Hsieh, Kai-Yu Lo, Huey-Kang Sytwu, Georges Vassaux y Tsu-Yi Chao. "Early Treg suppression by a Listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer (165.49)". Journal of Immunology 186, n.º 1_Supplement (1 de abril de 2011): 165.49. http://dx.doi.org/10.4049/jimmunol.186.supp.165.49.
Texto completoSantra, Sampa, Yue Sun, Jenny G. Parvani, Valerie Philippon, Michael S. Wyand, Kelledy Manson, Alicia Gomez-Yafal et al. "Heterologous Prime/Boost Immunization of Rhesus Monkeys by Using Diverse Poxvirus Vectors". Journal of Virology 81, n.º 16 (6 de junio de 2007): 8563–70. http://dx.doi.org/10.1128/jvi.00744-07.
Texto completoKaku, Chengzi I., Elizabeth R. Champney, Johan Normark, Marina Garcia, Carl E. Johnson, Clas Ahlm, Wanda Christ et al. "Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination". Science 375, n.º 6584 (4 de marzo de 2022): 1041–47. http://dx.doi.org/10.1126/science.abn2688.
Texto completoShaw, Robert H., Arabella Stuart, Melanie Greenland, Xinxue Liu, Jonathan S. Nguyen Van-Tam y Matthew D. Snape. "Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data". Lancet 397, n.º 10289 (mayo de 2021): 2043–46. http://dx.doi.org/10.1016/s0140-6736(21)01115-6.
Texto completoMichael, Nelson L. "Simplified steps to heterologous prime-boost HIV vaccine development?" Journal of Clinical Investigation 129, n.º 11 (30 de septiembre de 2019): 4572–73. http://dx.doi.org/10.1172/jci132440.
Texto completoGu, Yuan, Bin Zhan, Yaping Yang, Xiaodi Yang, Xi Zhao, Lei Wang, Jing Yang, Kuo Bi, Yunyun Wang y Xinping Zhu. "Protective Effect of a Prime-Boost Strategy with the Ts87 Vaccine againstTrichinella spiralisInfection in Mice". BioMed Research International 2014 (2014): 1–9. http://dx.doi.org/10.1155/2014/326860.
Texto completoHofer, Tamara, Matteo Rossi, Susanna Carboni, Wilma Di Berardino Besson, Dorothee von Laer, Guido Wollmann, Madiha Derouazi y Marie-Laure Santiago-Raber. "Heterologous Prime-Boost Vaccination with a Peptide-Based Vaccine and Viral Vector Reshapes Dendritic Cell, CD4+ and CD8+ T Cell Phenotypes to Improve the Antitumor Therapeutic Effect". Cancers 13, n.º 23 (3 de diciembre de 2021): 6107. http://dx.doi.org/10.3390/cancers13236107.
Texto completoXiao, Minglu, Luoyingzi Xie, Guoshuai Cao, Shun Lei, Pengcheng Wang, Zhengping Wei, Yuan Luo et al. "CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy". Journal for ImmunoTherapy of Cancer 10, n.º 5 (mayo de 2022): e004022. http://dx.doi.org/10.1136/jitc-2021-004022.
Texto completode Alencar, Bruna C. G., Pedro M. Persechini, Filipe A. Haolla, Gabriel de Oliveira, Jaline C. Silverio, Joseli Lannes-Vieira, Alexandre V. Machado, Ricardo T. Gazzinelli, Oscar Bruna-Romero y Mauricio M. Rodrigues. "Perforin and Gamma Interferon Expression Are Required for CD4+ and CD8+ T-Cell-Dependent Protective Immunity against a Human Parasite, Trypanosoma cruzi, Elicited by Heterologous Plasmid DNA Prime-Recombinant Adenovirus 5 Boost Vaccination". Infection and Immunity 77, n.º 10 (3 de agosto de 2009): 4383–95. http://dx.doi.org/10.1128/iai.01459-08.
Texto completoLemckert, Angelique A. C., Shawn M. Sumida, Lennart Holterman, Ronald Vogels, Diana M. Truitt, Diana M. Lynch, Anjali Nanda et al. "Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity". Journal of Virology 79, n.º 15 (1 de agosto de 2005): 9694–701. http://dx.doi.org/10.1128/jvi.79.15.9694-9701.2005.
Texto completoTenbusch, Matthias, Sofie Schumacher, Emanuel Vogel, Alina Priller, Jürgen Held, Philipp Steininger, Stephanie Beileke et al. "Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2". Lancet Infectious Diseases 21, n.º 9 (septiembre de 2021): 1212–13. http://dx.doi.org/10.1016/s1473-3099(21)00420-5.
Texto completoIkeno, Daisuke, Kazuhiko Kimachi, Yasuhiro Kudo, Shuro Goto, Shigeyuki Itamura, Takato Odagiri, Masato Tashiro y Yoichiro Kino. "A prime–boost vaccination of mice with heterologous H5N1 strains". Vaccine 27, n.º 23 (mayo de 2009): 3121–25. http://dx.doi.org/10.1016/j.vaccine.2009.01.007.
Texto completoRühl, Julia, Carmen Citterio, Christine Engelmann, Tracey Haigh, Andrzej Dzionek, Johannes Dreyer, Rajiv Khanna et al. "Heterologous prime-boost vaccination protects against EBV antigen–expressing lymphomas". Journal of Clinical Investigation 129, n.º 5 (15 de abril de 2019): 2071–87. http://dx.doi.org/10.1172/jci125364.
Texto completoLiu, Jinyan, Bonnie A. Ewald, Diana M. Lynch, Matthew Denholtz, Peter Abbink, Angelique A. C. Lemckert, Angela Carville et al. "Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys". Journal of Virology 82, n.º 10 (12 de marzo de 2008): 4844–52. http://dx.doi.org/10.1128/jvi.02616-07.
Texto completoMeurisse, Marjan, Lucy Catteau, Joris A. F. van Loenhout, Toon Braeye, Laurane De Mot, Ben Serrien, Koen Blot et al. "Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium". Vaccines 11, n.º 2 (7 de febrero de 2023): 378. http://dx.doi.org/10.3390/vaccines11020378.
Texto completoDangi, Tanushree, Nicole Palacio, Sarah Sanchez, Mincheol Park, Jacob Class, Lavanya Visvabharathy, Thomas Ciucci, Igor J. Koralnik, Justin Richner y Pablo Penaloza Macmaster. "Cross-protection by SARS vaccines is improved by booster vaccination". Journal of Immunology 208, n.º 1_Supplement (1 de mayo de 2022): 125.21. http://dx.doi.org/10.4049/jimmunol.208.supp.125.21.
Texto completoGola, Anita, Adam A. Walters, Stefan Uderhardt, Ahmed M. Salman, Benedict R. Halbroth, Shahid M. Khan, Chris J. Janse, Ronald N. Germain, Alexandra J. Spencer y Adrian VS Hill. "Prime and Target Immunization Protects Against Liver-Stage Malaria". Journal of Immunology 198, n.º 1_Supplement (1 de mayo de 2017): 199.13. http://dx.doi.org/10.4049/jimmunol.198.supp.199.13.
Texto completoSuphanchaimat, Rapeepong, Natthaprang Nittayasoot, Chuleeporn Jiraphongsa, Panithee Thammawijaya, Punsapach Bumrungwong, Atthavit Tulyathan, Nontawit Cheewaruangroj, Chakkarat Pittayawonganon y Piyanit Tharmaphornpilas. "Real-World Effectiveness of Mix-and-Match Vaccine Regimens against SARS-CoV-2 Delta Variant in Thailand: A Nationwide Test-Negative Matched Case-Control Study". Vaccines 10, n.º 7 (5 de julio de 2022): 1080. http://dx.doi.org/10.3390/vaccines10071080.
Texto completoMüller-Hilke, Brigitte, Franz Mai, Michael Müller, Johann Volzke y Emil C. Reisinger. "Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2". Vaccines 10, n.º 2 (17 de febrero de 2022): 322. http://dx.doi.org/10.3390/vaccines10020322.
Texto completoThorner, Anna R., Angelique A. C. Lemckert, Jaap Goudsmit, Diana M. Lynch, Bonnie A. Ewald, Matthew Denholtz, Menzo J. E. Havenga y Dan H. Barouch. "Immunogenicity of Heterologous Recombinant Adenovirus Prime-Boost Vaccine Regimens Is Enhanced by Circumventing Vector Cross-Reactivity". Journal of Virology 80, n.º 24 (11 de octubre de 2006): 12009–16. http://dx.doi.org/10.1128/jvi.01749-06.
Texto completoKim, Dong-In, Seo Jin Lee, Soonju Park, Paul Kim, Sun Min Lee, Nakyung Lee, David Shum, Dong Ho Kim y Eui Ho Kim. "Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19". Vaccines 10, n.º 11 (4 de noviembre de 2022): 1864. http://dx.doi.org/10.3390/vaccines10111864.
Texto completoHo, Tzu-Chuan, Yi-Ming Arthur Chen, Hung-Pin Chan, Chin-Chuan Chang, Kuo-Pin Chuang, Che-Hsin Lee, Cheng-Hui Yuan, Yu-Chang Tyan y Ming-Hui Yang. "The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2". Vaccines 9, n.º 10 (11 de octubre de 2021): 1163. http://dx.doi.org/10.3390/vaccines9101163.
Texto completoMollenkopf, Hans Joachim, Leander Grode, Jens Mattow, Maik Stein, Peggy Mann, Bernhard Knapp, Jeffrey Ulmer y Stefan H. E. Kaufmann. "Application of Mycobacterial Proteomics to Vaccine Design: Improved Protection by Mycobacterium bovis BCG Prime-Rv3407 DNA Boost Vaccination against Tuberculosis". Infection and Immunity 72, n.º 11 (noviembre de 2004): 6471–79. http://dx.doi.org/10.1128/iai.72.11.6471-6479.2004.
Texto completoParys, Anna, Elien Vandoorn, Koen Chiers, Katharina Passvogel, Walter Fuchs, Thomas C. Mettenleiter y Kristien Van Reeth. "Exploring Prime-Boost Vaccination Regimens with Different H1N1 Swine Influenza A Virus Strains and Vaccine Platforms". Vaccines 10, n.º 11 (29 de octubre de 2022): 1826. http://dx.doi.org/10.3390/vaccines10111826.
Texto completoXing, Zhou y Thomas James Charters. "Heterologous boost vaccines for bacillus Calmette–Guérin prime immunization against tuberculosis". Expert Review of Vaccines 6, n.º 4 (agosto de 2007): 539–46. http://dx.doi.org/10.1586/14760584.6.4.539.
Texto completoMoore, Anne C. y Adrian V. S. Hill. "Progress in DNA-based heterologous prime-boost immunization strategies for malaria". Immunological Reviews 199, n.º 1 (junio de 2004): 126–43. http://dx.doi.org/10.1111/j.0105-2896.2004.00138.x.
Texto completoLiu, J., H. Li, M. J. Iampietro y D. H. Barouch. "Accelerated Heterologous Adenovirus Prime-Boost SIV Vaccine in Neonatal Rhesus Monkeys". Journal of Virology 86, n.º 15 (16 de mayo de 2012): 7829–35. http://dx.doi.org/10.1128/jvi.00512-12.
Texto completoSchneider, Jorg, Sarah C. Gilbert, Carolyn M. Hannan, Pilar Degano, Eric Prieur, Eric G. Sheu, Magdalena Plebanski y Adrian V. S. Hill. "Induction of CD8+ T cells using heterologous prime-boost immunisation strategies". Immunological Reviews 170, n.º 1 (agosto de 1999): 29–38. http://dx.doi.org/10.1111/j.1600-065x.1999.tb01326.x.
Texto completoSantra, Sampa, Yue Sun, Birgit Korioth-Schmitz, Julie Fitzgerald, Cherie Charbonneau, Giannina Santos, Michael S. Seaman et al. "Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors". Vaccine 27, n.º 42 (septiembre de 2009): 5837–45. http://dx.doi.org/10.1016/j.vaccine.2009.07.050.
Texto completoAbel, Kristina, Lisa Strelow, Yujuan Yue, Meghan K. Eberhardt, Kimberli A. Schmidt y Peter A. Barry. "A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus". Vaccine 26, n.º 47 (noviembre de 2008): 6013–25. http://dx.doi.org/10.1016/j.vaccine.2008.07.103.
Texto completoHe, Ran. "Efficient control of chronic LCMV infection by CD4 T cell epitope-based heterologous prime-boost vaccination in a murine model". Journal of Immunology 198, n.º 1_Supplement (1 de mayo de 2017): 123.10. http://dx.doi.org/10.4049/jimmunol.198.supp.123.10.
Texto completoMichiels, Yves, Nadhira Houhou-Fidouh, Gilles Collin, Jérôme Berger y Evelyne Kohli. "Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient". Vaccines 9, n.º 10 (6 de octubre de 2021): 1140. http://dx.doi.org/10.3390/vaccines9101140.
Texto completoRaposo, Francisco y Giuseppe Lippi. "Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy". Clinica Chimica Acta 523 (diciembre de 2021): 201–4. http://dx.doi.org/10.1016/j.cca.2021.09.022.
Texto completoKim, Jaejo, Seung-Heon Lee, Ha-Hyun Kim, Jong-Hyeon Park y Choi-Kyu Park. "Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs". Vaccines 11, n.º 3 (25 de febrero de 2023): 551. http://dx.doi.org/10.3390/vaccines11030551.
Texto completoBenning, Louise, Maximilian Töllner, Asa Hidmark, Matthias Schaier, Christian Nusshag, Florian Kälble, Paula Reichel et al. "Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers". Vaccines 9, n.º 8 (4 de agosto de 2021): 857. http://dx.doi.org/10.3390/vaccines9080857.
Texto completoHovav, Avi-Hai, Mark J. Cayabyab, Michael W. Panas, Sampa Santra, John Greenland, Ralf Geiben, Barton F. Haynes, William R. Jacobs y Norman L. Letvin. "Rapid Memory CD8+ T-Lymphocyte Induction through Priming with Recombinant Mycobacterium smegmatis". Journal of Virology 81, n.º 1 (18 de octubre de 2006): 74–83. http://dx.doi.org/10.1128/jvi.01269-06.
Texto completoBarouch, Dan H., Paul F. McKay, Shawn M. Sumida, Sampa Santra, Shawn S. Jackson, Darci A. Gorgone, Michelle A. Lifton et al. "Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 Vaccines". Journal of Virology 77, n.º 16 (15 de agosto de 2003): 8729–35. http://dx.doi.org/10.1128/jvi.77.16.8729-8735.2003.
Texto completoWalther, Michael, Fiona M. Thompson, Susanna Dunachie, Sheila Keating, Stephen Todryk, Tamara Berthoud, Laura Andrews et al. "Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein". Infection and Immunity 74, n.º 5 (mayo de 2006): 2706–16. http://dx.doi.org/10.1128/iai.74.5.2706-2716.2006.
Texto completoOrlinger, Klaus Karl, Weldy V. Bonilla, Sandra M. Kallert, Nicole Kirchhammer, Anna-Friederike Marx, Magdalena Krzyzaniak, Sarah Schmidt et al. "Arenavirus-based vector platform for massive tumor self-antigen-specific CD8 T cell immunity." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): e14297-e14297. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14297.
Texto completoKim, Silvia, Jeffrey Currier, Josephine Cox, Jean-Louis Excler, Eddy Sayeed, Merlin Robb, Jerome Kim, Nelson Michael y Mary Marovich. "Cellular immunogenicity of an Ad35GGRIN+ENV and MVA-CMDR prime-boost vaccine regimen. (42.3)". Journal of Immunology 184, n.º 1_Supplement (1 de abril de 2010): 42.3. http://dx.doi.org/10.4049/jimmunol.184.supp.42.3.
Texto completoSabarth, Nicolas, M. Keith Howard, Helga Savidis-Dacho, André van Maurik, P. Noel Barrett y Otfried Kistner. "Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model". Vaccine 28, n.º 3 (enero de 2010): 650–56. http://dx.doi.org/10.1016/j.vaccine.2009.10.105.
Texto completoValdés, Iris, Lázaro Gil, Yaremis Romero, Jorge Castro, Pedro Puente, Laura Lazo, Ernesto Marcos, María G. Guzmán, Gerardo Guillén y Lisset Hermida. "The Chimeric Protein Domain III-Capsid of Dengue Virus Serotype 2 (DEN-2) Successfully Boosts Neutralizing Antibodies Generated in Monkeys upon Infection with DEN-2". Clinical and Vaccine Immunology 18, n.º 3 (5 de enero de 2011): 455–59. http://dx.doi.org/10.1128/cvi.00382-10.
Texto completoFiander, A. N., A. J. Tristram, E. J. Davidson, A. E. Tomlinson, S. Man, P. J. Baldwin, J. C. Sterling y H. C. Kitchener. "Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial". International Journal of Gynecologic Cancer 16, n.º 3 (2006): 1075–81. http://dx.doi.org/10.1136/ijgc-00009577-200605000-00020.
Texto completo